Business Context and Reporting Period
Company: BioLife Solutions, Inc. (BLFS)
Filing Type: Form 8-K (Current Report)
Date of Report: July 21, 2026
Reporting Period: The filing covers the entry into a definitive merger agreement on July 21, 2026, and references preliminary unaudited revenue results for the second quarter ended June 30, 2026.
Key Financial Metrics and Transaction Terms
Merger Consideration: BioLife shareholders will receive a mixed consideration package per share of BioLife Common Stock:
- Cash: $11.25 per share.
- Stock: 0.1442 shares of Repligen Corporation common stock.
Equity Awards Treatment: Outstanding options, RSUs, PSUs, and RSAs will accelerate vesting in full and convert into the right to receive the Merger Consideration.
Financial Results: The filing references a press release (Exhibit 99.1) containing preliminary unaudited revenue for the second quarter ended June 30, 2026. However, the specific revenue, profit, cash flow, margin, debt, or liquidity figures are not disclosed within the text of this 8-K filing.
Material Changes and Transaction Structure
Acquirer: Repligen Corporation.
Structure: A two-step merger where BioLife becomes a wholly-owned subsidiary of Repligen.
Expected Closing: Fourth quarter of 2026, subject to customary conditions.
Conditions to Closing:
- Approval by BioLife stockholders.
- SEC effectiveness of the Form S-4 registration statement.
- Antitrust clearance (HSR Act waiting period expiration).
- Listing approval of Repligen stock on Nasdaq.
- Absence of material adverse effects or legal restraints.
Guidance, Risks, and Contingencies
Termination Fee: BioLife may be required to pay Repligen a termination fee of $59,000,000 under specific circumstances, including:
- Repligen terminating due to a change in BioLife's board recommendation.
- BioLife terminating to enter a superior proposal.
- Failure to obtain stockholder approval where a competing proposal was announced.
- Termination due to the "Outside Date" (January 31, 2027) if a competing proposal was communicated.
Outside Date: The agreement may be terminated if not consummated by January 31, 2027. This date may extend automatically by 180 days if only antitrust or restraint conditions remain, or by 90 days if the SEC registration statement is not effective by November 30, 2026.
Risks and Uncertainties:
- Failure to obtain regulatory approvals or stockholder approval.
- Integration challenges and failure to realize anticipated synergies.
- Diversion of management attention from ongoing operations.
- Potential dilution of Repligen shareholders.
- Market conditions affecting the cell therapy industry.
Investor Verification Checklist
- Merger Consideration Value: Verify the total value of the offer ($11.25 cash + 0.1442 Repligen shares) against current market prices of Repligen stock.
- Stockholder Approval: Confirm the date and outcome of the BioLife stockholders' meeting required to approve the merger.
- Regulatory Status: Monitor the status of the HSR Act waiting period and any other antitrust reviews.
- Form S-4 Filing: Review the upcoming proxy statement/prospectus (Form S-4) for detailed financial projections, risk factors, and voting instructions.
- Q2 2026 Results: Locate Exhibit 99.1 (Joint Press Release) to obtain the specific preliminary revenue figures for the quarter ended June 30, 2026, which are not detailed in this summary text.
- Termination Triggers: Assess the likelihood of the $59 million termination fee being triggered based on market activity and regulatory timelines.